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Paris, FranceSee Article, pages 1253–1259Among the challenges that care of patients with cirrhosis brings,
management of periprocedural bleeding risk is a common con-
cern as chronic liver disease (CLD) implies the need for frequent
invasive diagnostic and therapeutic procedures, such as biopsies,
variceal band ligation or percutaneous ablation of hepatocellular
carcinoma.
In this issue of the Journal of Hepatology, Terrault et al. report
the results of a phase II multicentre, randomized, placebo-con-
trolled study of a 7-day pre-procedural administration of ava-
trombopag, a second-generation thrombopoietin receptor
agonist in patients with cirrhosis and thrombocytopenia
(<58,000/ll) [1]. Most interventions consisted of dental proce-
dures and gastrointestinal endoscopies. Two formulations of ava-
trombopag were tested in two separate cohorts. Patients received
one of the ﬁve doses of the drug or placebo. The primary end
point was an increase of at least 20,000/ll platelets from baseline
and a total platelet count over 50,000/ll between days 4 and 8
after the ﬁrst dose. Overall, 48% of patients receiving the study
drug reached this end point vs. 8% in the placebo group. The level
of increase of the platelet count was highest with the highest
dose administered. Transfusion of platelets was not a study end
point and not standardized across study sites; therefore no con-
clusion could be drawn about this aspect. There was no difference
in total or serious adverse events between patients treated with
avatrombopag and those receiving placebo. Yet, one patient
receiving the ﬁrst-generation formulation of avatrombopag at
the highest dose (100/80 mg) was found to have a portal vein
thrombosis (PVT) after having reached a maximal platelet count
of 199,000/ll.
Moderate degrees of thrombocytopenia in CLD are not associ-
ated with increased bleeding, presumably because platelet aggre-Journal of Hepatology 20
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Open access under CC BY-NC-ND license.gation is preserved as a consequence of increased levels of
circulating von Willebrand factor and decreased activity of its
cleaving protease, ADAMTS13 [2,3]. However, for more profound
degrees of thrombocytopenia, the risk of bleeding increases. On
top of their role in primary haemostasis (platelet aggregation),
platelets also contribute to secondary haemostasis (coagulation).
Indeed, thrombin generation in the presence of thrombomodulin
decreases together with platelet counts in patients with cirrhosis
[4]. This appears to be especially true when the platelet count is
below 60,000/ll. Conversely, when platelet numbers are adjusted
to those of controls, the plasma of patients with cirrhosis gener-
ates equal amounts of thrombin. This effect may involve the
phospholipid surface that platelets provide for the activation of
the prothrombinase complex. A clear threshold of platelet counts,
below which the bleeding risk clearly increases, cannot be pro-
posed, but the following data provide some insight. In patients
from the HALT-C trial, 75% of liver biopsy-related haemorrhages
occurred in patients with platelet counts below 60,000/ll [5].
In an Italian study, analysing bleeding events after common diag-
nostic and therapeutic interventions in 125 patients with cirrho-
sis and thrombocytopenia, bleeding occurred in 32% of those with
platelet counts below 75,000/ll, compared to none of those with
platelet counts between 75 and 150,000/ll [6]. The platelet count
was a better predictor of bleeding than the international normal-
ized ratio (INR).
Thrombocytopenia in cirrhosis is of multifactorial origin
(Fig. 1), resulting from splenic sequestration of platelets,
increased destruction of platelets within the spleen, intrasplenic
production of autoantibodies, plasma expansion resulting in hae-
modilution and decreased activity of thrombopoietin [7]. The
liver is an important site of thrombopoietin production. Levels
of circulating thrombopoietin, as well as those of messenger
RNA in hepatocytes, are decreased in patients with cirrhosis
and are restored in the weeks following liver transplantation
[8–10].
This study by Terrault et al. is important because it is the ﬁrst
published experience of the second-generation thrombopoietin
receptor agonist avatrombopag in patients with CLD and paves
the way for a larger, phase III trial. Experience from the ﬁrst-gen-14 vol. 61 j 1199–1201
Favouring 
haemostasis/thrombosis
Favouring
bleeding
Increased circulating levels of vWF
Decreased ADAMTS13 production
TPO receptor agonists
Platelet activation
Trombocytopenia related to:
• Splenic sequestration of platelets 
• Reduced hepatic synthesis of TPO
• Low-grade disseminated intravascular 
coagulation
• Antiplatelet antibodies leading to splenic 
destruction
• Medullar toxicity of alcohol and HCV
Fig. 1. Changes in primary haemostasis in patients with chronic liver disease. TPO receptor agonists not only increase platelet counts but also enhance platelet
activation and function. The balance between thrombosis and bleeding is fragile in chronic liver disease patients. HCV, hepatitis C virus; TPO, thrombopoietin; vWF, von
Willebrand Factor.
Editorialeration thrombopoietin receptor agonists, romiplostim and
eltrombopag, in patients with CLD warrants a note of caution.
Romiplostim, a parenteral thrombopoietin analogue adminis-
tered weekly, seemed promising in raising platelet counts before
elective minor surgeries (mostly cataract, hernia and fracture ﬁx-
ation) in patients with Child-Pugh C hepatitis C-related cirrhosis
and severe thrombocytopenia (<50,000/ll) in a small single-cen-
tre, single-arm, open-label Egyptian study [11]. In the ELEVATE
trial, 292 patients with thrombocytopenia (<50,000/ll) and CLD
were randomized to receive eltrombopag or placebo for 14 days
before an invasive procedure, again mostly dental or endoscopic
[12]. The drug avoided platelet transfusions in a large number of
patients (72% vs. 19%). However, PVT developed in 4% of patients
in the eltrombopag group as compared to 1% in the placebo
group. This ﬁnding led to the early termination of the trial.
Eltrombopag has also been tested in patients with hepatitis C-
related cirrhosis and thrombocytopenia to increase platelet
counts and permit interferon-based therapy. In a ﬁrst placebo-
controlled study of 72 patients with platelet counts between
20,000 and 70,000/ll, 75% to 95% of patients treated with differ-
ent doses of eltrombopag for 4 weeks reached platelet counts
over 100,000/ll and initiated interferon treatment, compared to
none in the placebo group [13]. Adverse events were comparable
between groups. In the larger ENABLE-1 and 2 trials, 1520
patients with baseline thrombocytopenia (<75,000/ll) infected
with hepatitis C virus and candidates for pegylated interferon
therapy received eltrombopag or placebo during antiviral treat-
ment after a documented response to eltrombopag [14]. The
use of eltrombopag, when compared with placebo, permitted
higher doses of interferon and was associated with higher sus-
tained virological response rates (23% vs. 14%, p = 0.0064 in
ENABLE-1 and 19% vs. 13%, p = 0.0202 in ENABLE-2). However, a
signiﬁcantly higher incidence of thromboembolic events was
observed in the eltrombopag group (3% vs. 1%). One third of these
events were PVT. Importantly, hepatic decompensation occurred
twice more commonly in patients receiving eltrombopag. This
result is in line with the beneﬁcial effect of anticoagulation and1200 Journal of Hepatology 2014antiplatelet drugs on liver ﬁbrosis in animal models [15], and
with the protective effect of prophylactic doses of enoxaparin
on liver decompensation in patients with cirrhosis [16].
The other indication for the use of thrombopoietin receptor
agonists is refractory idiopathic thrombocytopenic purpura. A
meta-analysis of currently available randomized controlled trials
comprising 1180 patients described a statistically non-signiﬁcant
trend towards an increased thromboembolic risk [17]. The
thrombotic risk associated with thrombopoietin receptor ago-
nists could even be higher in CLD patients than in those without
liver disease. The efﬁcacy of thrombopoiesis, generated by throm-
bopoietin receptor agonists, in CLD patients could be one of the
factors responsible for the increased thrombotic risk. In the ELE-
VATE trial, 5 of the 6 patients with PVT had a maximal platelet
count over 200,000/ll. In the study by Terrault et al., the maximal
platelet count recorded in the patient with PVT was 199,000/ll.
Splenic sequestration of platelets in CLD yields lower total plate-
let counts and may lead to underestimation of the thrombopoie-
sis, generated by these drugs. Other factors, including decreased
portal blood ﬂow and hypercoagulability, associated with cirrho-
sis, may synergize with the increase in platelet counts, due to
thrombopoietin receptor agonists to promote portal vein throm-
bosis in CLD patients [4,18].
It is now widely recognized that haemostasis in patients with
CLD is ‘‘rebalanced’’ [19]. Studies concerning the use of thrombo-
poietin receptor agonists have demonstrated that this rebalance
is fragile and that a tendency to bleed can easily be shifted to a
tendency to clot in the individual patient. Thrombopoietin recep-
tor agonists, including avatrombopag, raise platelet counts in a
dose-dependent manner. Important questions remain to be
answered before thrombopoietin receptor agonists can be safely
used in patients with cirrhosis: (a) How can the procedure-
related bleeding risk in individual patients be better predicted?
(b) What is the safety window in platelet counts, induced by
thrombopoietin receptor agonists, to reduce the bleeding risk
without exposing the patient to thrombosis? (c) Is the risk of liver
decompensation really increased with elevated platelet counts orvol. 61 j 1199–1201
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other effects of thrombopoietin receptor agonists? (d) What are
the risk factors for developing PVT or liver decompensation in
patients receiving thrombopoietin receptor agonists? Hopefully,
the ongoing phase III randomized placebo-controlled trial of ava-
trombopag prior to an invasive procedure in patients with CLD
and platelet counts below 50,000/ll (National Clinical Trials
identiﬁers NCT01976104 and NCT01972529) will bring elements
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